Published on 19 May 2023 on Zacks via Yahoo Finance
Regeneron (REGN) Faces Challenges as Eylea Sales Decline
Regeneron Pharmaceuticals, Inc. REGN lost 6.3% in a month compared with the industry’s decline of 2.8%.
Earlier in the month, Regeneron delivered better-than-expected first-quarter 2023 results. However, lead drug Eylea (aflibercept) sales declined. Shares declined in response to the same.
Lead drug Eylea’s sales in the United States were $1.4 billion, down 6% year over year, primarily due to an increase in sales-related deductions. Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY.